Abstract
Aims Insulin resistance (IR) is a characteristic feature of heart failure (HF) pathophysiology that affects symptoms and mortality. Differences in the pathophysiological profile of IR in HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) are not characterized in detail. The aim of this study was to evaluate features of IR in HFpEF vs. HFrEF. Methods and results We included 18 patients with HFrEF (EF 30 ± 11%, body mass index (BMI) 26.5 ± 3.3 kg/m2), 22 HFpEF patients (EF 63 ± 7%, BMI 28.6 ± 4.8 kg/m2), and 20 healthy controls of similar age, all without diabetes mellitus. Patients were in stable ambulatory condition and on stable medical regimens for HF. IR was assessed at fasting steady state by the homeostasis model assessment (HOMA) index and within the physiological range of insulin-glucose interactions by the short insulin sensitivity test (SIST). Fasting-state IR was observed in HFpEF and in HFrEF in comparison with controls (HOMA 1.9, interquartile range (IQR) 1.5-3.6 vs. HOMA 3.1, IQR 1.4-3.7 vs. controls 1.2, IQR 1.8-0.9, respectively; analysis of variance P <0.001), but no statistical difference was observed between HFpEF and HFrEF. The dynamic test over the physiological range of insulin-glucose interactions revealed a more severe IR in HFrEF as compared with HFpEF. Thus, glucose levels remained the highest in HFrEF (76 (64-89) mg/dL) at the end of the SIST compared with HFpEF and controls (68 (58-79) and 56 (44-66) mg/dL, respectively, P <0.001). Conclusion IR is present in non-diabetic patients with HFpEF and HFrEF. However, distinct differences in the insulin sensitivity characteristics in HFpEF and HFrEF become apparent by more advanced testing. Patients with HFrEF showed more severe IR.
| Original language | English |
|---|---|
| Pages (from-to) | 1015-1021 |
| Number of pages | 7 |
| Journal | European Journal of Heart Failure |
| Volume | 17 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - Oct 1 2015 |
Fingerprint
Keywords
- DEXA
- HFpEF
- HFrEF
- HOMA
- Insulin resistance
- Short insulin sensitivity test
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Insulin resistance in heart failure : Differences between patients with reduced and preserved left ventricular ejection fraction. / Scherbakov, Nadja; Bauer, Maximiliane; Sandek, Anja; Szabõ, Tibor; Töpper, Agnieszka; Jankowska, Ewa A.; Springer, Jochen; Von Haehling, Stephan; Anker, Stefan D.; Lainscak, Mitja; Engeli, Stefan; Düngen, Hans Dirk; Doehner, Wolfram.
In: European Journal of Heart Failure, Vol. 17, No. 10, 01.10.2015, p. 1015-1021.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Insulin resistance in heart failure
T2 - Differences between patients with reduced and preserved left ventricular ejection fraction
AU - Scherbakov, Nadja
AU - Bauer, Maximiliane
AU - Sandek, Anja
AU - Szabõ, Tibor
AU - Töpper, Agnieszka
AU - Jankowska, Ewa A.
AU - Springer, Jochen
AU - Von Haehling, Stephan
AU - Anker, Stefan D.
AU - Lainscak, Mitja
AU - Engeli, Stefan
AU - Düngen, Hans Dirk
AU - Doehner, Wolfram
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Aims Insulin resistance (IR) is a characteristic feature of heart failure (HF) pathophysiology that affects symptoms and mortality. Differences in the pathophysiological profile of IR in HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) are not characterized in detail. The aim of this study was to evaluate features of IR in HFpEF vs. HFrEF. Methods and results We included 18 patients with HFrEF (EF 30 ± 11%, body mass index (BMI) 26.5 ± 3.3 kg/m2), 22 HFpEF patients (EF 63 ± 7%, BMI 28.6 ± 4.8 kg/m2), and 20 healthy controls of similar age, all without diabetes mellitus. Patients were in stable ambulatory condition and on stable medical regimens for HF. IR was assessed at fasting steady state by the homeostasis model assessment (HOMA) index and within the physiological range of insulin-glucose interactions by the short insulin sensitivity test (SIST). Fasting-state IR was observed in HFpEF and in HFrEF in comparison with controls (HOMA 1.9, interquartile range (IQR) 1.5-3.6 vs. HOMA 3.1, IQR 1.4-3.7 vs. controls 1.2, IQR 1.8-0.9, respectively; analysis of variance P <0.001), but no statistical difference was observed between HFpEF and HFrEF. The dynamic test over the physiological range of insulin-glucose interactions revealed a more severe IR in HFrEF as compared with HFpEF. Thus, glucose levels remained the highest in HFrEF (76 (64-89) mg/dL) at the end of the SIST compared with HFpEF and controls (68 (58-79) and 56 (44-66) mg/dL, respectively, P <0.001). Conclusion IR is present in non-diabetic patients with HFpEF and HFrEF. However, distinct differences in the insulin sensitivity characteristics in HFpEF and HFrEF become apparent by more advanced testing. Patients with HFrEF showed more severe IR.
AB - Aims Insulin resistance (IR) is a characteristic feature of heart failure (HF) pathophysiology that affects symptoms and mortality. Differences in the pathophysiological profile of IR in HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) are not characterized in detail. The aim of this study was to evaluate features of IR in HFpEF vs. HFrEF. Methods and results We included 18 patients with HFrEF (EF 30 ± 11%, body mass index (BMI) 26.5 ± 3.3 kg/m2), 22 HFpEF patients (EF 63 ± 7%, BMI 28.6 ± 4.8 kg/m2), and 20 healthy controls of similar age, all without diabetes mellitus. Patients were in stable ambulatory condition and on stable medical regimens for HF. IR was assessed at fasting steady state by the homeostasis model assessment (HOMA) index and within the physiological range of insulin-glucose interactions by the short insulin sensitivity test (SIST). Fasting-state IR was observed in HFpEF and in HFrEF in comparison with controls (HOMA 1.9, interquartile range (IQR) 1.5-3.6 vs. HOMA 3.1, IQR 1.4-3.7 vs. controls 1.2, IQR 1.8-0.9, respectively; analysis of variance P <0.001), but no statistical difference was observed between HFpEF and HFrEF. The dynamic test over the physiological range of insulin-glucose interactions revealed a more severe IR in HFrEF as compared with HFpEF. Thus, glucose levels remained the highest in HFrEF (76 (64-89) mg/dL) at the end of the SIST compared with HFpEF and controls (68 (58-79) and 56 (44-66) mg/dL, respectively, P <0.001). Conclusion IR is present in non-diabetic patients with HFpEF and HFrEF. However, distinct differences in the insulin sensitivity characteristics in HFpEF and HFrEF become apparent by more advanced testing. Patients with HFrEF showed more severe IR.
KW - DEXA
KW - HFpEF
KW - HFrEF
KW - HOMA
KW - Insulin resistance
KW - Short insulin sensitivity test
UR - http://www.scopus.com/inward/record.url?scp=84946478746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946478746&partnerID=8YFLogxK
U2 - 10.1002/ejhf.317
DO - 10.1002/ejhf.317
M3 - Article
C2 - 26198713
AN - SCOPUS:84946478746
VL - 17
SP - 1015
EP - 1021
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1388-9842
IS - 10
ER -